| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10213230 | International Journal of Cardiology | 2018 | 7 Pages |
Abstract
Rosuvastatin increases LDL-EV coagulation proteins plasminogen and VWF in patients with subclinical atherosclerosis, an effect that is different from the effect of rosuvastatin on the same proteins in serum. This identifies LDL-EVs as a newly detected possible intermediate between statin therapy and coagulation.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Laura Verbree-Willemsen, Ya-Nan Zhang, Crystel M. Gijsberts, Arjan H. Schoneveld, Jiong-Wei Wang, Carolyn S.P. Lam, Floor Vernooij, Michiel L. Bots, Linda M. Peelen, Diederick E. Grobbee, Joel S. Raichlen, Dominique P.V. de Kleijn,